Hyundai Bioscience Balance Sheet Health
Financial Health criteria checks 6/6
Hyundai Bioscience has a total shareholder equity of ₩46.4B and total debt of ₩5.4B, which brings its debt-to-equity ratio to 11.6%. Its total assets and total liabilities are ₩53.7B and ₩7.3B respectively.
Key information
11.6%
Debt to equity ratio
₩5.40b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩3.86b |
| Equity | ₩46.41b |
| Total liabilities | ₩7.32b |
| Total assets | ₩53.73b |
Recent financial health updates
Recent updates
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Mar 14
Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07
Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher
Jan 03The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Nov 29Financial Position Analysis
Short Term Liabilities: A048410's short term assets (₩16.2B) exceed its short term liabilities (₩6.7B).
Long Term Liabilities: A048410's short term assets (₩16.2B) exceed its long term liabilities (₩602.9M).
Debt to Equity History and Analysis
Debt Level: A048410's net debt to equity ratio (3.3%) is considered satisfactory.
Reducing Debt: A048410's debt to equity ratio has reduced from 34.7% to 11.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A048410 has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: A048410 is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.